Healthy Clinical Trial
Official title:
A Single-ascending and Multiple-ascending Dose Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension
The purpose of this study is to measure side effects of LY3971297 injection administered under the skin in healthy participants and obese participants with high blood pressure (BP). Blood tests will be performed to check how much LY3971297 gets into the bloodstream and how long it takes the body to eliminate it. This is a 5-part study. The study duration will be approximately 60 days for Part A and approximately 90 days for Parts B, C, D, and E.
Status | Recruiting |
Enrollment | 188 |
Est. completion date | December 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - For Parts A, B, C, E, Overtly healthy males or females as determined by medical history and physical examination. - For Parts A, B, C, E, have a screening body mass index (BMI) in the range of 18.5 to 35 kg/m2, inclusive, with no significant weight gain or loss in the past 3 months prior to screening. - For Part C, to qualify as Chinese for the purpose of this study, all the participants' biological grandparents must be of exclusive Chinese descent and born in China - For Part Part D, participants with obesity and hypertension must have a stable dose of antihypertensive medications within the past 3 months prior to screening. - For Part D, obesity BMI in the range of 30 to 40 kg/m2, inclusive, with a waist circumference of at least 102 cm for men and at least 89 cm for women. - For Part E, to qualify as a participant of the first-generation Japanese origin, the participant, the participant's biological parents, and all of the participants' biological grandparents must be of exclusive Japanese descent and born in Japan. - Male participants must agree to adhere to contraception restrictions and female participants must be women not of childbearing potential. Exclusion Criteria: - Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders - Have known or ongoing psychiatric disorders that, in the opinion of the investigator, increases the risks associated with study participation - Have blood pressure and/or pulse rate constituting a risk as determined by the investigator. - Have a systolic BP of less than 100 mmHg. - Diagnosed with orthostatic hypotension defined as a decrease in systolic blood pressure of equal to or greater than 20 mmHg or a decrease in diastolic blood pressure of equal to or greater than 10 mmHg when compared with BP from the supine position. - For US sites: have donated blood of more than 500 mL within the previous 3 months of screening or intend to donate blood during the course of the study. - For Singapore sites: Have donated blood of more than 450 mL or more in the past 3 months or provided any blood donation within the past 1 month before screening - Consume more than 10 cigarettes per day (or the equivalent) or are unable or unwilling to abstain from nicotine. - Have alcohol intake that exceeds recommended alcohol consumption limits per local regulation, or are unwilling to stop alcohol consumption 24 hours prior to dosing until discharge. - For Part D, has concurrent use or anticipated use of phosphodiesterase 5 inhibitor such as vardenafil, tadalafil, and sildenafil, soluble guanylyl cyclase activators (such as riociguat and vericiguat). - For Part D, has concurrent or anticipated use of long-acting nitrates or NO donors. - For Part D, has concurrent or anticipated use of beta blockers. - For Part D, has current use of more than 3 mechanism of actions for treatment of hypertension. |
Country | Name | City | State |
---|---|---|---|
Singapore | Lilly Centre for Clinical Pharmacology | Singapore | |
United States | CenExel ACT | Anaheim | California |
United States | ICON Early Phase Services | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Eli Lilly and Company |
United States, Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Part A: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module | Baseline (Day of Exposure) to Day 29 post-dose | |
Primary | Part B, C, D, & E: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Part B, C, D, & E: A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module | Baseline (Day of Exposure) to Day 57 post-dose | |
Secondary | Pharmacokinetics (PK): Area Under the Concentration curve (AUC) of LY3971297 | PK: AUC of LY3971297 | Predose on day 1 up to 29 days post dose for Part A and predose on day 1 up to 57 days post dose for Part B, C, D, and E | |
Secondary | PK: Maximum Observed Drug Concentration (Cmax) of LY3971297 | PK: Cmax of LY3971297 | Predose on day 1 up to 29 days post dose for Part A and predose on day 1 up to 57 days post dose for Part B, C, D, and E |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |